For the quarter ending 2025-09-30, ENSCW had -$538,357 decrease in cash & cash equivalents over the period. -$1,989,822 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,729,128 | -3,679,090 |
| Accrued interest | 3,161 | 6,107 |
| Change in fair value of liability classified warrants | 998 | 9,063 |
| Consultant compensation | 50,717 | 203,014 |
| Amortization of orginal issue discount and debt issuance costs | - | 0 |
| Stock-based compensation | 45,858 | 106,889 |
| Unbilled receivable | -1,200,568 | 1,080,864 |
| Prepaid expenses and other assets | -779,709 | -1,185 |
| Accounts payable | -579,374 | -314,247 |
| Accrued expenses and other liabilities | 363,308 | 351,789 |
| Net cash used in operating activities | -1,866,179 | -4,414,280 |
| Investment in property and equipment | 123,643 | - |
| Net cash used in investing activities | -123,643 | - |
| Repayment of convertible notes | - | 0 |
| Proceeds from public offerings | 0 | 1,100,007 |
| Proceeds from warrant exercises | 1,496,854 | 390,855 |
| Proceeds from warrant inducement, net of issuance costs | 0 | 2,200,012 |
| Transaction costs from public offerings | 0 | 204,193 |
| Transaction costs associated with warrant inducements | 5,410 | 291,611 |
| Repayment of financed insurance premiums | 39,979 | 71,292 |
| Net cash provided by financing activities | 1,451,465 | 3,123,778 |
| Increase (decrease) in cash and cash equivalents | -538,357 | -1,290,502 |
| Cash and cash equivalents at beginning of period | 3,502,077 | - |
| Cash and cash equivalents at end of period | 1,673,218 | - |
Ensysce Biosciences, Inc. (ENSCW)
Ensysce Biosciences, Inc. (ENSCW)